Division of Biosurface technology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Science and Technology, Poojappura, Thiruvananthapuram 695012, Kerala, India.
Colloids Surf B Biointerfaces. 2011 Jul 1;85(2):221-8. doi: 10.1016/j.colsurfb.2011.02.032. Epub 2011 Mar 16.
Our study focuses on the incorporation of β-CD into the HA structure, its effects on the phase of HA and the biological responses to proteins and blood cells. Hydroxyapatite (HA) containing levels of β-cyclodextrin (β-CD) of upto 0.9 wt% has been produced by co-precipitation method. The complexes were analyzed by X-ray diffraction (XRD), transmission electron microscopy (TEM), Fourier transform infrared (FT-IR) spectroscopy, thermal gravimetric analysis (TG) and differential scanning analysis (DSC) methods. The size of the complexes as analyzed using DLS (dynamic light scattering) was between 150 nm and 350 nm. The results show that an increase in concentration of β-CD in the prepared samples that leads to an increase in hydrophobicity seems to promote an affinity for albumin adsorption. The PAGE results were substantiated by Lowry measurements and the results reveal that the H2 (containing 0.7 wt% β-CD) sample shows around 40% increase in albumin adsorption when compared to the H1 (containing 0.5 wt% β-CD) sample. The preferential adsorption of albumin has not been demonstrated in vivo. The ability to design particles that can preferentially interact with particular protein can obtain desired targeting effects. So the results indicate that HA/β-CD complexes have immense potential in targeted delivery of drugs. The in vivo potential of the developed samples was further confirmed in vitro by the results of cell aggregation and haemolytic activity.
我们的研究集中在将β-CD 纳入 HA 结构中，研究其对 HA 相的影响以及对蛋白质和血细胞的生物反应。通过共沉淀法制备了含有高达 0.9wt%β-环糊精（β-CD）的羟基磷灰石（HA）。通过 X 射线衍射（XRD）、透射电子显微镜（TEM）、傅里叶变换红外（FT-IR）光谱、热重分析（TG）和差示扫描分析（DSC）方法对复合物进行了分析。使用动态光散射（DLS）分析复合物的大小在 150nm 至 350nm 之间。结果表明，在制备的样品中β-CD 浓度的增加导致疏水性增加，似乎促进了白蛋白吸附的亲和力。PAGE 结果通过 Lowry 测量得到证实，结果表明，与 H1（含 0.5wt%β-CD）样品相比，H2（含 0.7wt%β-CD）样品的白蛋白吸附量增加了约 40%。尚未在体内证明白蛋白的优先吸附。能够设计能够优先与特定蛋白质相互作用的颗粒可以获得所需的靶向效果。因此，结果表明 HA/β-CD 复合物在药物靶向递送方面具有巨大的潜力。通过细胞聚集和溶血活性的体外结果进一步证实了开发样品的体内潜力。
